APONTIS PHARMA Reports Strong Half-Year Growth in 2024

APONTIS PHARMA AG has reported significant revenue growth for its Single Pill combinations in the first half of 2024. The company saw its revenue leap to EUR 17.9 million, a substantial increase from EUR 12.1 million in H1 2023.

This growth was boosted by a new cooperation with Novartis on asthma products, contributing EUR 2.5 million. The company achieved an EBITDA of EUR 2.1 million, a sharp improvement from a loss of EUR 4.0 million in the same period last year, mainly due to a reduced cost base and higher sales.

The net result turned positive at EUR 0.7 million, improving from a loss of EUR 3.5 million in H1 2023. APONTIS PHARMA has confirmed its raised forecast for the full year, expecting sales to reach EUR 50.7 million with a positive EBITDA of EUR 3.3 million.